drugset / Trial / NCT03994796
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Phase 2
Active not recruiting
50 enrolled
Alliance for Clinical Trials in Oncology
Eli Lilly and Company · collabGenentech, Inc. · collabKazia Therapeutics Limited · collabMirati Therapeutics Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
Timeline
- Start
- 2019-10-17
- Primary completion
- 2026-10
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Adagrasib | Small molecule | — | Oral |
| Subject | Entrectinib | Small molecule | — | Oral |
| Subject | Paxalisib | Small molecule | — | Oral |